menu003.png

NEW GRANT FROM CDTI TO DEVELOP QTX125 HDAC6 SELECTIVE INHIBITOR

CDTI has approved a Neotec grant of 212.475€ to QUIMATRYX in support of the project “QUIMATRYX: DESARROLLO DE FÁRMACOS EPIGENÉTICOS”.

Thanks to this grant, Quimatryx will continue with the preclinical development of its most advanced HDAC6 inhibitor, QTX125, which is highly selective and active against this epigenetic target.

QTX125 has shown potent antitumoural activity in animal model against pancreatic cancer and, B-cell lymphomas. In addition, QTX125 has shown high efficacy in autoimmune disease animal models, such as multiple sclerosis.

 

   QUIMATRYX

   Paseo Mikeletegi 69, 3ª planta

   20009 San Sebastián

   Tel: 946 08 70 37

   www.quimatryx.com